Trans Genic Group, Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Drug Discovery Support Business and Investment and Consulting Business. The Drug Discovery Support Business segment provides seamless services that can handle all stages of drug discovery, from the initial stages of exploratory basic research and drug discovery research to non-clinical trials and clinical trials. The Investment and Consulting Business segment provides advice and support services related to the promotion of new businesses and includes retail and wholesale of electrical products, B2C and B2B. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company